| Project/Area Number |
16K10610
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Teikyo University |
|---|
Principal Investigator |
Wada Keita 帝京大学, 医学部, 准教授 (80349307)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
飯沼 久恵 帝京大学, 医学部, 講師 (30147102)
佐野 圭二 帝京大学, 医学部, 教授 (00334392)
三浦 文彦 帝京大学, 医学部, 准教授 (00344995)
|
|---|
| Project Period (FY) |
2016-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 膵癌 / マイクロRNA / miRNA / micro RNA / micor RNA / バイオマーカー / 癌 |
|---|
| Outline of Final Research Achievements |
In order to examine the significance of microRNA (miRNA) as a biomarker in pancreatic cancer, miRNA expression was measured using a blood sample collected from a pancreatic cancer patient. First, the miRNA array was performed and compared with healthy subjects to extract miRNAs highly specific to pancreatic cancer. Next, we compared the miRNA-451a expression level with clinicopathological factors using blood samples collected before surgery for patients with resected pancreatic cancer. As a result, the miR-451a high expression group was significantly higher than the low expression group. Recurrence-free survival and shortened overall survival were observed. Similar results were obtained in portal blood samples that were perfusion of tumor, suggesting that miRNA may be a predictor of recurrence and prognosis in pancreatic cancer.
|
| Academic Significance and Societal Importance of the Research Achievements |
膵癌は難治性がんの一つであり、患者全体の5年生存率は欧米、日本で6-7%と推定されている。膵癌が予後不良であることの一因は有効な早期診断法がなく、ほぼ全例が診断された時点で進行癌であることがあげられる。膵癌治療成績の向上のためには早期診断も然ることながら、治療効果モニタリングに有用なバイオマーカーの開発が不可欠である。今回の検討でmiRNAが膵癌における有用なバイオマーカーである可能性が示されたことから、今後の研究により早期発見、危険群の選別、治療効果予測などへの応用が期待される。
|
